Falcon Reminiscent acquires Brand Tech Enterprises
2nd May 2053
The deal was long rumored for some time among the business circles, but the company declined to comment them until this day when the deal actually took place. By buying Brand Tech Enterprises Falcon Reminiscent takes the lead position of the US market in gene technology services of the private sector. The CEO Ulric Terrell comments the acquisition:
"This acquisition supports our strategy to provide a cross-screen connection for clients, creators and third-party operators to deliver the best possible technology. This is a unique opportunity that will redefine the germinal technology industry and create a company able to offer new bundles and customized services, not only in the States, but also in the Latin America."
Falcon Reminiscent was founded in 2044 by Sekar Saito. Initially its main business was to develop alternative genetic engineering methods to CRISPR, which were still the standard in the business despite of its known shortcomings. During the first years the company had only little over 200 employees. Falcon Reminiscent had its first main breakthrough when they figured out a new method manipulate epigenetics, the GRT-tunneling. This was a major innovation in the field of genetics, which raised the company to the league of leading genetic engineering companies of the world.
Although the rumors weren’t far-fetched considering recent developments of the company, very few saw this coming. In recent years Falcon Reminiscent have been suffering some serious financial problems, being also on the verge of bankruptcy two years back. After receiving an initial recovery investment of US$91 million in venture capital, led by Capital Forage, in May 2049 Falcon Reminiscent took an additional round of investment totaling US$244 million. Now four years later the company had grown to 200 000 employees and reached profitability by the 1st quarter of 2052. After this positive turn the company ended up buying it’s competitor Brand Tech Liberties.
Malaria will be eradicated soon
24th April 2053
Thanks to advancements in genetic engineering, Malaria will be soon eradicated. For two decades there have been several yet unsuccesful attempts to eliminate Plasmodium, genus of parasitic protozoa, many of which cause malaria in their hosts. International team of scientists, brought together by the World Healt Organization, have reached several major milestones, but the final blow against the disease have still been a work in progress. Now the international team has just announced the development of a new malaria drug soon ready for mass production.
The best results so far was creation of "mosqiller", genetically engineered virus against Anopheles, mosquito species spreading the disease. However, Mosqiller was apparently too effective, causing some unwanted side effects on the local ecosystem when tested on remote village in South-East asia. Unfortunately the mosquito is a very vital part of dietary for many animals, which rendered the solution out of the question.
The same team who created the mosqiller have now created another virus attacks the parasitic protozoa without harming their host mosquitos. This new attempt against Malaria, has already been tested on the field in South-East Asia. ”The disease itself and the complexity of generating an artificial virus against it, is by far the biggest challenge I’ve faced on my career”, says head of the team, lead biologist Azariah Williams. ”The recent field trials with gave us an opportunity to assess how far we still have to go, and ensure this time the virus isn’t affecting the local ecosystem in any unpredictable way. So far we have got very promising results. Our intention to attack to a certain portion of the parasite's life cycle seems to work splendidly. At the moment it looks like it (Malaria) will soon join the other recently exterminated diseases like Poliomyelitis and Dracunculiasis. All thanks to the modern genetic engineering.”
CMG's 42nd birthday to be celebrated
2nd March 2053
NHGRI, one of the 27 institutes and centers at the National Institutes of Health, founded the CMG, the Centers for Mendelian Genomics in 2011. The program’s overarching aim is to systematically identify the genomic causes of Mendelian diseases, which are rare disorders that tend to be caused by mutations in a single gene. To date, more than 9,800 Mendelian diseases have been described, and researchers have found the underlying genomic causes for about 5,400 of them.
By sequencing and analyzing the protein-coding portions of more than 20,000 human genomes, CMG investigators have identified over 2480 genes that likely cause Mendelian diseases. CMG researchers have also developed and disseminated tools that enable scientists to rapidly discover such genes. “Rare diseases provide an important window into the biology of both rare and common diseases,” says Carlie Atkins, Ph.D., director of the CMG program. CMG investigators will continue to apply genome sequencing and analysis to find genes that cause Mendelian diseases, with a focus on novel genes, she said. NHGRI, pending available funds, will provide $70 million to support the CMG program.
Additional information about NHGRI and CMG can be found at www.genome.gov.